Our society is more mobile than ever, and with the threat of diseases like Ebola and the Zika virus ever-present across the globe, an epidemic can spread fast. It is important to invest in the prevention and treatment of these diseases, and that is why we are committed to the advancement of infectious disease research and vaccines through biopharmaceutical research.

Chiltern has a team of medical professionals who can handle patient enrollment for any disease and for even the most novel compounds and delivery mechanisms — adding support and value to your project. Working as a cross-functional group, the team collaborates with you to provide infectious disease drug and vaccine development advice from medical, operational, regulatory and cost-efficiency perspectives. The relationships they foster with industry leaders and key professionals allow them to provide deeper insights and strategic guidance, leading to better patient experiences, improved clinical outcomes and expedited regulatory approvals.

Over the last five years, Chiltern has conducted 62 infectious disease and vaccines studies.

Infectious Disease & Vaccines

Investigators
Patients
Countries
Total Studies

Top Infectious Disease & Vaccines Indications From the Past Five Years

  • AIDS/HIV
  • Anti-infectives and pharmacokinetics
  • Chronic HCV-1/HIV-1
  • Chronic hepatitis B
  • Community acquired pneumonia
  • Cytomegalovirus (CMV) infection
  • Gastrointestinal infections
  • Hepatitis C (HCV) – acute and chronic
  • Hereditary angioedema
  • Impetigo
  • Lupus
  • Respiratory syncytial virus (RSV)
  • Respiratory tract infections
  • Tinea corporis
  • Vaccines
    • Anthrax
    • Cholera
    • Combined
    • Influenza (H1N1 and H5N1)
    • Smallpox
  • Ventilator-associated pneumonia
  • Viral infections

Let us help you reach your program’s goals with a comprehensive range of collaborative services: